EURURO Vol. 72 No. 5

695 860

Table 3 – Contemporary retrospective studies evaluating outcomes and predictors of response in prostate cancer patients undergoing salvage radiotherapy (sRT)
Patients
(N
)
Pre-RT
PSA level(median)
Technique
Concomitant
ADT
Dose
(median)
Studyperiod
Follow-up(median)
Outcomes
Predictors of
response to sRT
Ost et al
136
0.8 ng/ml
IMRT
71% ptsreceived ADT
76 Gy
1999–2008 5 yr
5-yr BCR-free survival: 56%5-yr CR-free survival: 86%
Perineural invasionPre-RT PSA levelsADT administration
Cotter et al
[41]
519
NA
NA
NA
66 Gy
1988–2008 11.3 yr
sRT associated with significantreduction in the risk of overall mortality
NA
Moreira et al
102
0.6 ng/ml
NA
No
66 Gy
1988–2008 50 mo
6-yr BCR-free survival: 57%
Surgical marginsPre-RT PSA levels
Bernard et al
364
0.6 ng/ml
NA
NA
64.8 Gy
1987–2007 6 yr
5-yr BCR-free survival: 50%
RT dose
Umezawa et al
102
0.24 ng/ml
NA
28% ptsreceived ADT
64 Gy
2000–2009 44 mo
4-yr BCR-free survival: 50.9%
Pathologic stage
Siegmann et al
301
0.28 ng/ml
NA
No
66.6-70.2Gy
1997–2007 30 mo
2-yr BCR-free survival: 74%
Total doseBiochemical responseSeminal vesicle invasion
Goenka et al
285
0.4 ng/ml
3D-CRT or IMRT 31% pts
received ADT
NA
1988–2007 60 mo
7-yr BCR-free survival: 37%7-yr CR-free survival: 77%
Vascular invasionSurgical marginsPre-RT PSA levelsADT
Jackson et al
575
NA
3D-CRT or IMRT 20% pts
received ADT
68.4 Gy
1986–2010 56.7 mo
The median time to BCR was 15.2 vs21.8 mo for patients with for patientswith Gleason pattern 5 vs Gleason 8
Gleason pattern 5Pathologic stageSurgical marginsPre-RT PSA levelsADT
Ploussard et al
[51]
201
0.48 ng/ml
NA
No
NA
1998–2011 53.3 mo
BCR was reported in 42.8% of caseswith the need for second-line ADTin 26.9% of cases
Gleason scorePathologic stagePSA velocityPre-RT PSA levels
Kwon et al
[46]
212
0.46 ng/ml
Pelvicirradiationin 25% of pts
58.2% ptsreceived ADT
66.6 Gy
2003–2012 63.5 mo
5-yr BCR-free survival: 58.2%
Pre-RT PSA levelsPSADTADTSurgical margins
Parekh et al
108
0.24 ng/ml
NA
40% ptsreceived ADT
66.49 Gy 1993–2010 63.09 mo
4-yr BCR-free survival 44.6% vs 22.8% forpatients who received ADT vs no ADT
Pre-RT PSA levelsADT
Ervandian et al
[42]
259
NA
NA
50% ptsreceived ADT
NA
2006–2010 NA
3-yr BCR-free survival: 57%
Surgical marginsADTPre-RT PSA levels
Song et al
[53]
149
0.54 ng/ml
3D-CRT or IMRT NA
69.2 Gy
1995–2011 82 mo
5-yr BCR-free survival: 53.6%
Pre-RT PSA levelsPathologic stageGleason scorePSADTPre-RT imaging
van der Poel et al
[57]
157
0.2 ng/ml
3D-CRT to theprostatic fossa
No
66–70 Gy 2006–2011 36 mo
3-yr BCR-free survival: 64%
pN stagePre-RT PSA levels
Lohm et al
151
0.34 ng/ml
3D-CRT
No
66.6 Gy
NA
82 mo
BCR-free survival: 40%OS: 87%CSS: 92%
Pre-RT PSA levelsGleason scorePSADT
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 6 8 9 – 7 0 9 695